LVS vs STRO · P/E 28, rev $2.90B vs rev $62.0M
Las Vegas Sands Corp (LVS) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Las Vegas Sands Corp (LVS) is a resorts & casinos company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported LVS revenue for 2024-12-31 was $2.90B. Net income was $392.0M. Revenue was up 8.0% from 2024-09-30 to 2024-12-31. LVS currently screens at market cap $35.70B and trailing P/E 28.3.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
LVS currently screens at market cap $35.70B and trailing P/E 28.3. STRO currently screens at market cap $470.8M.
Not investment advice. Open the LVS and STRO stock pages for the full models.
Not investment advice.